1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Zoetis
  6. Summary
    ZTS   US98978V1035

ZOETIS

(ZTS)
  Report
Delayed Nyse  -  05/17 04:04:06 pm EDT
166.43 USD   +0.56%
05/05GLOBAL MARKETS LIVE : BAE, Shell, Berkshire Hathaway, Nissan, Shopify...
05/05Zoetis Cuts 2022 Guidance on Foreign Exchange Drag After First-Quarter Beat
MT
05/05ZOETIS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
159.9(c) 163.08(c) 165.33(c) 165.5(c) 166.43 Last
3 355 238 2 396 632 2 239 300 2 457 657 1 871 878 Volume
-1.69% +1.99% +1.38% +0.10% +0.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 8 322 M - -
Net income 2022 2 209 M - -
Net Debt 2022 2 343 M - -
P/E ratio 2022 35,3x
Yield 2022 0,76%
Sales 2023 9 061 M - -
Net income 2023 2 455 M - -
Net Debt 2023 1 015 M - -
P/E ratio 2023 31,2x
Yield 2023 0,86%
Capitalization 77 889 M 77 889 M -
EV / Sales 2022 9,64x
EV / Sales 2023 8,71x
Nbr of Employees 12 100
Free-Float 93,7%
More Financials
Company
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (54.7%): cats and dogs (94.1% of net sales) and horses (5.9%); - livestock (44.1%): cattle (53% of sales), swine (21.1%), poultry (18.3%), fish (5%) and other (1.2%); - other (1.2%). Net sales break down by family of products into vaccines (22.1%), anti-infectives... 
Sector
Pharmaceuticals
Calendar
05/19 | 08:00amShareholder meeting
More about the company
Ratings of Zoetis
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ZOETIS
05/05GLOBAL MARKETS LIVE : BAE, Shell, Berkshire Hathaway, Nissan, Shopify...
05/05Zoetis Cuts 2022 Guidance on Foreign Exchange Drag After First-Quarter Beat
MT
05/05ZOETIS INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
05/05SECTOR UPDATE : Health Care Stocks Decline Premarket Thursday
MT
05/05TRANSCRIPT : Zoetis Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Zoetis 1Q Net Profit Climbs on Strong Demand for Pet Medicine
DJ
05/05Zoetis Cuts 2022 Earnings, Revenue View on Foreign-Exchange Impact
DJ
05/05Stocks Signal Weaker Opening as Futures Trade Lower Pre-Bell; Asia Mixed, Europe Higher
MT
05/05Zoetis Q1 Adjusted Earnings, Revenue Rise; Company Revises 2022 Outlook Downward
MT
05/05ZOETIS : Q1 Earnings Snapshot
AQ
05/05Earnings Flash (ZTS) ZOETIS Reports Q1 Revenue $1.99B
MT
05/05GUIDANCE : (ZTS) ZOETIS Expects Fiscal Year 2022 EPS Range $4.99 - $5.09
MT
05/05GUIDANCE : (ZTS) ZOETIS Sees Fiscal Year 2022 Revenue Range $8.23B - $8.38B
MT
05/05Earnings Flash (ZTS) ZOETIS Posts Q1 EPS $1.32
MT
05/05Wall Street Leans Back Pre-Bell; Futures Red, Europe Up, Asia Muted
MT
More news
News in other languages on ZOETIS
05/05MISE À JOUR SECTORIELLE : Les actions du secteur de la santé chutent jeudi avant le marché
05/05Les actions signalent une ouverture plus faible alors que les Futures s'échangent à la ..
05/05Hausse du bénéfice ajusté et du chiffre d'affaires de Zoetis au premier trimestre ; la ..
05/05GUIDANCE : (ZTS) ZOETIS prévoit une fourchette de BPA pour l'exercice 2022 de 4,99 à 5,09 ..
05/05GUIDANCE : (ZTS) ZOETIS prévoit une fourchette de revenus pour l'exercice 2022 de 8,23 à 8..
More news
Analyst Recommendations on ZOETIS
More recommendations
Chart ZOETIS
Duration : Period :
Zoetis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOETIS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 165,50 $
Average target price 238,09 $
Spread / Average Target 43,9%
EPS Revisions
Managers and Directors
Kristin C. Peck Chief Executive Officer & Director
Wetteny Joseph CFO, EVP & Head-Business Development
Michael B. McCallister Non-Executive Chairman
Wafaa Mamilli Chief Information & Digital Officer
Robert J. Polzer Executive VP, President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZOETIS-32.18%77 889
ELANCO ANIMAL HEALTH INCORPORATED-17.86%11 051
DECHRA PHARMACEUTICALS PLC-38.33%4 359
BLUESTAR ADISSEO COMPANY-23.30%3 744
VIRBAC-15.55%3 151
VIMIAN GROUP AB (PUBL)-32.26%2 075